RxDoctor Payments Data

Fines Shaw

Psychiatric/Mental Health · Beaumont, CANPI 1467095224

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,246 of the $12,653 with a category attached, or 65.2%. 20 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 40.0% of the total. 2025 is the largest year on record at $8,840, 6.5 times the $1,355 reported in 2023. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,653in general payments, 2019–2025

Across 365 payments — averaging $34.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$5K
  • Neurocrine Biosciences, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Johnson & Johnson$916
  • AbbVie$773
  • Alkermes, Inc.$637
  • plus $3K from 14 others

What the payments were for

  • Consulting fees$3,30026%
  • Travel & lodging$7896%
  • Food & beverage$8,24665%
  • Education$3193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,653 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$157,902
Invega SustennaPaliperidone Palmitate12$39,324
VraylarCariprazine Hcl12$16,968
Oxcarbazepine24$1,655
Olanzapine152$1,598
Divalproex Sodium ErDivalproex Sodium50$1,403
Desmopressin Acetate23$1,119
Quetiapine Fumarate ErQuetiapine Fumarate36$783
Divalproex Sodium43$743
Aripiprazole84$733
Quetiapine Fumarate72$619
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$547
Lamotrigine32$517
Risperidone75$477
Clonazepam82$449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,644$157,90221 claims
Johnson & JohnsonInvega Sustenna$916$39,32412 claims
AbbVieVraylar$773$16,96812 claims
Almatica Pharma LLCSertraline Hcl$18$29966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Beaumont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →